Novo Nordisk A/S ADR (NVO) Stock Price, Quote & News

Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The c...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 45 44 44 88 88

Website: www.novonordisk.com

Address:

Novo Alle 1, Bagsvaerd, Denmark

trader_556 Mar. 5 at 2:17 AM

$NVO not yet bottomed. Staying on cash to DCA if it drops below 30…

1 · Reply

TheinvestmetABCD Mar. 5 at 2:04 AM

$NVO this will had to $50+ by the end of this year with a 90% probability, no matter the broader market!

0 · Reply

TrumpTrainz2024 Mar. 5 at 1:07 AM

$NVO Howard what’s up with the glitch?

0 · Reply

ChetBTW Mar. 5 at 1:06 AM

$NVO 👀

0 · Reply

jam500 Mar. 5 at 12:19 AM

$NVO 40$ tomorrow .

0 · Reply

BioRich Mar. 4 at 11:18 PM

$ALT Y'all going to check this out when $VERU highlights "Moving beyond BMI & Weight Loss Endpoints"? Looks like their combination with $NVO will be highlighted for it's muscle sparing capabilities. Would be nice to see data and claims that are defensible. Still waiting to see those comparator arm data for $ALT's LMP claims. Still believed to have shown better LMP in the Placebo arm than the Pemvi arm for $ALT. Cheers!

0 · Reply

BioRich Mar. 4 at 11:11 PM

$VERU Love that Veru is leading this Workshop. What an opportunity to showcase the excellent profile of Veru's lean mass preservation combinations with $NVO.

0 · Reply

BioRich Mar. 4 at 10:56 PM

$VERU Haven't forgotten about you. Keep preserving that muscle and let's get a damn deal done! Here are some highlights from the upcoming "4th Obesity & Weight Loss Drug Development Summit." (July 14th-16) The summit specifically highlights $VERU in the same bullets as $NVO, $LLY and $RHHBY and calling them "Innovative Biotech" along with Canary and $MTSR For those interested, here's the link to the Summit and downloading the Agenda is free with this link: Summit Link: https://obesity-weight-loss-summit.com/?utm_source=marketo&utm_medium=email&utm_campaign=primary&utm_content=launch/ev-69725/em-01 Event Guide Link: https://obesity-weight-loss-summit.com/full-event-guide/?utm_source=marketo&utm_medium=email&utm_campaign=primary&utm_content=launch/ev-69725/em-01

0 · Reply

DeepValueFinders Mar. 4 at 10:32 PM

$NVO $45 by weeks end

2 · Reply

_TheRisingMoons Mar. 4 at 10:15 PM

$XOM $NVO $MSTR $ASTS //

0 · Reply

GLP-1 drugs protect against new or worsening addictions, large study shows

Wed, 04 Mar 2026 12:41:39 -0500 - 9 hours ago

Looking For A Rebound? China Tech and Emerging Markets Top Oversold List

2026-03-04T14:15:48.000Z - 12 hours ago

Novo Nordisk Gets FDA Warning Over Ozempic Ad

2026-03-04T13:56:15.000Z - 13 hours ago

Novo Nordisk (NVO) Faces FDA Warning Over Ozempic Ad

2026-03-04T13:23:24.000Z - 13 hours ago

Novo Nordisk gets another FDA warning over GLP-1 ad claims

2026-03-03T22:27:09.000Z - 1 day ago

Bearish Sentiment Surrounds Novo Nordisk (NVO) Amid Stock Decline

Tue, 03 Mar 2026 17:12:16 -0500 - 1 day ago

US FDA warns Novo for second time about misleading Ozempic advertising

Tue, 03 Mar 2026 16:25:00 -0500 - 1 day ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO

2026-03-03T17:09:49.000Z - 1 day ago

Aspen expects Canada nod for generic targeting Novo’s Ozempic by September

2026-03-03T17:05:00.000Z - 1 day ago

Novo Nordisk Addresses Economic Risks of Obesity on World Obesity Day

2026-03-03T16:04:10.000Z - 1 day ago

Novo Nordisk AS (NVO) Trading Down 4.42% on Mar 3

Tue, 03 Mar 2026 10:11:05 -0500 - 1 day ago

4 Factor Dividend Growth Strategy Remains Ahead Of Its Benchmark

Tue, 03 Mar 2026 07:13:33 -0500 - 1 day ago

Pricing Pressure And Panic: What The Market May Be Missing In Novo Nordisk

Tue, 03 Mar 2026 01:26:38 -0500 - 1 day ago

Roche targets double-digit market share in weight loss, aims to catch up with Novo Nordisk, Handelsblatt reports

2026-03-02T17:56:03.000Z - 2 days ago

Goldman Sachs Downgrades Novo Nordisk (NVO) After CagriSema Results

Mon, 02 Mar 2026 12:00:00 -0500 - 2 days ago

Why I'm Not Worried About Novo Nordisk Stock

2026-03-02T16:54:04.000Z - 2 days ago

Novo Nordisk downgraded at Goldman Sachs on disappointing CagriSema data

2026-03-02T16:49:24.000Z - 2 days ago

Novo Nordisk to Invest $506 Million in Ireland for Wegovy Production

2026-03-02T16:42:56.000Z - 2 days ago

Novo Nordisk to Spend â¬432 Million Expanding Irish Wegovy Production

Mon, 02 Mar 2026 10:57:15 -0500 - 2 days ago

Why Novo Nordisk's Ireland expansion is key to fighting off Eli Lilly

Mon, 02 Mar 2026 10:55:00 -0500 - 2 days ago

Election of employee representatives to the Board of Directors of Novo Nordisk A/S

Mon, 02 Mar 2026 10:30:27 -0500 - 2 days ago

Monday's Market Movers: CRWD Rallies, NVO Downgrade, BRK/B Earnings

2026-03-02T13:28:52.000Z - 2 days ago

Novo Nordisk confirms €432m investment in Athlone plant

2026-03-02T13:04:41.000Z - 2 days ago

This Novo Nordisk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday

2026-03-02T12:01:00.000Z - 2 days ago

Health Canada Approves Ozempic® (semaglutide injection) to Reduce the Risk of Major Adverse Cardiovascular Events (MACE) in Adults with Type 2 Diabetes

2026-03-02T11:46:37.000Z - 2 days ago

€400m weight loss tablet factory to be built in Ireland

Mon, 02 Mar 2026 06:22:00 -0500 - 2 days ago

Novo Nordisk A/S - share repurchase programme

Mon, 02 Mar 2026 04:23:42 -0500 - 2 days ago

Novo Nordisk to invest $506 million in Ireland plant expansion

Mon, 02 Mar 2026 04:00:00 -0500 - 2 days ago

Novo Nordisk announces more than 400 million euro expansion in its manufacturing facility in Athlone, Ireland

2026-03-01T17:31:10.000Z - 3 days ago

Novo Nordisk, First Solar, And Corebridge Financial Are Among Top 10 Large Cap Losers Last Week (Feb. 23-Feb. 27): Are the Others in Your Portfolio?

2026-03-01T14:05:41.000Z - 3 days ago

Notable healthcare headlines for the week: Viatris, Novo Nordisk, and Gilead Sciences in focus

Sun, 01 Mar 2026 08:10:06 -0500 - 3 days ago

14 Ideal 'Safer' Dividend Buys From 29 Of 69 March Graham Value All-Stars (GVAS)

2026-02-28T16:56:21.000Z - 4 days ago

Novo Nordisk (NVO) Faces Tough Month Amid Competitive Pressures

2026-02-28T11:42:10.000Z - 4 days ago

Benzinga Bulls And Bears: Rocket Lab, Kosmos Energy, Novo Nordisk — And Nvidia Fails To Boost Markets

2026-02-28T06:16:00.000Z - 4 days ago

Anthropic vs. The Pentagon: what enterprises should do

2026-02-27T21:25:43.000Z - 5 days ago

FDA Approves Novo Nordisk's Sogroya for New Pediatric Indications (NVO)

2026-02-27T14:39:27.000Z - 5 days ago

Novo Nordisk Shares Sink 21% as Obesity Shot Trails Lilly Rival

Fri, 27 Feb 2026 06:33:45 -0500 - 5 days ago

Why I'm Still Bullish On Novo Nordisk Despite Recent Setbacks

2026-02-27T09:48:00.000Z - 5 days ago

Got $5,000? Hims & Hers Could Be a Direct‑to‑Consumer Health Moonshot in the Making

2026-02-26T22:00:19.000Z - 6 days ago

Novo Nordisk: A Trap, Not A Trade (Rating Upgrade)

Thu, 26 Feb 2026 16:40:00 -0500 - 6 days ago

Forget Altimmune: This Proven Obesity‑Drug Giant Is the Better Weight‑Loss Play

Thu, 26 Feb 2026 15:39:27 -0500 - 6 days ago

Why Shares of Novo Nordisk Stock Sank (Again) This Week

Thu, 26 Feb 2026 15:18:00 -0500 - 6 days ago

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO

Thu, 26 Feb 2026 06:17:53 -0500 - 6 days ago

Novo Nordisk: Can't Ignore It At These Valuations (Rating Upgrade)

Wed, 25 Feb 2026 17:52:08 -0500 - 7 days ago

Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies

Wed, 25 Feb 2026 13:00:00 -0500 - 7 days ago

1 Reason Why I'd Hold This Weight‑Loss Drug Leader Through Any Market Crash

Wed, 25 Feb 2026 11:33:38 -0500 - 7 days ago

Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment

2026-02-25T16:33:38.000Z - 7 days ago

Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment

2026-02-25T14:56:54.000Z - 7 days ago

Novo Nordisk Strikes Up to $2.1B Vivtex Deal for Oral Obesity Drugs

Wed, 25 Feb 2026 09:56:00 -0500 - 7 days ago

NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm

Feb 25, 2026, 9:13 AM EST - 7 days ago

Ozempic Price War - Novo Nordisk Slashes Prices By 50%

Feb 25, 2026, 8:53 AM EST - 7 days ago

Novo Nordisk, Vivtex to Develop Obesity Drugs in Deal Valued at Up to $2.1 Billion

Feb 25, 2026, 8:03 AM EST - 7 days ago

Novo Nordisk partners with Vivtex in up to $2.1 billion deal for oral obesity drugs

Feb 25, 2026, 8:00 AM EST - 7 days ago

Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes

Feb 25, 2026, 5:32 AM EST - 7 days ago

These 4 charts show the scale of Novo Nordisk's woes

Feb 24, 2026, 4:08 PM EST - 8 days ago

Novo Nordisk: The New PayPal?

Feb 24, 2026, 3:38 PM EST - 8 days ago

Healthy Returns: What's next for Novo Nordisk's next-generation obesity drug CagriSema after trial miss

Feb 24, 2026, 3:26 PM EST - 8 days ago

Ozempic, Wegovy prices to drop up to 50% as Novo Nordisk's rivalry with Eli Lilly heats up: report

Feb 24, 2026, 1:51 PM EST - 8 days ago

Novo Nordisk to slash list prices of Ozempic, Wegovy by up to 50%

Feb 24, 2026, 9:00 AM EST - 8 days ago

Ozempic And Wegovy Prices Will Be Cut Next Year, Drug-Maker Says

Feb 24, 2026, 9:00 AM EST - 8 days ago

Novo Nordisk: Investors Focusing On CagriSema Results Are Missing The Big Picture

Feb 24, 2026, 8:54 AM EST - 8 days ago

Novo Nordisk to slash GLP-1 list prices by up to 50% in U.S. to cut costs for insured patients

Feb 24, 2026, 8:10 AM EST - 8 days ago

Novo Nordisk to cut US list prices of Ozempic, Wegovy as of 2027

Feb 24, 2026, 7:51 AM EST - 8 days ago

Novo Nordisk and Eli Lilly shares both fall after Ozempic price-cut plan

LLY

Feb 24, 2026, 7:48 AM EST - 8 days ago

Novo Nordisk Is Cutting Ozempic and Wegovy Prices. The Stock Is Still Slumping.

Feb 24, 2026, 7:42 AM EST - 8 days ago

Novo Nordisk to slash US list prices of Ozempic and Wegovy, WSJ reports

Feb 24, 2026, 7:30 AM EST - 8 days ago

Novo Nordisk will slash the list prices for its popular drugs Wegovy and Ozempic by as much as half starting next year

Feb 24, 2026, 5:55 AM EST - 8 days ago

NVO Stock: Should You Buy The Dip?

Feb 24, 2026, 4:12 AM EST - 8 days ago

Analyst says he's thrown in the towel on Novo Nordisk after latest setback

Feb 24, 2026, 4:11 AM EST - 8 days ago

Novo Nordisk, United Laboratories Say New Obesity Drug Helps Patients Lose Weight in Trial

Feb 24, 2026, 3:50 AM EST - 8 days ago

Novo Nordisk, United Biotechnology obesity drug trial shows 19.7% weight loss

Feb 24, 2026, 3:45 AM EST - 8 days ago

Barclays slashes sales forecasts for Novo's CagriSema by more than 80%

Feb 24, 2026, 3:39 AM EST - 8 days ago

Novo Nordisk: Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China

Feb 24, 2026, 12:09 AM EST - 8 days ago

Novo's stumbles burnish Lilly's widening lead in weight-loss drugs

LLY

Feb 23, 2026, 12:12 PM EST - 9 days ago

Novo Nordisk shares sink after weight loss drug fails to match Eli Lilly's in trial

Feb 23, 2026, 12:00 PM EST - 9 days ago

Novo Nordisk A/S Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – NVO

Feb 23, 2026, 11:42 AM EST - 9 days ago

Novo Nordisk's Loss Is Eli Lilly's Gain

LLY

Feb 23, 2026, 11:35 AM EST - 9 days ago

Novo Nordisk Tumbles in 'Worst Case Scenario': Next-Gen Weight Loss Drug Underperforms

Feb 23, 2026, 11:32 AM EST - 9 days ago

Stock Of The Day: Breakdown In Novo Nordisk?

Feb 23, 2026, 11:16 AM EST - 9 days ago

Novo Nordisk Stock Tumbles Monday to Its Lowest Point in Nearly 5 Years. Here's Why

Feb 23, 2026, 10:20 AM EST - 9 days ago

Novo Nordisk CSO on New Obesity Shot Results and Drug Pipeline

Feb 23, 2026, 9:54 AM EST - 9 days ago

Novo Nordisk: Redefine 4 Misses The Mark

trader_556 Mar. 5 at 2:17 AM

$NVO not yet bottomed. Staying on cash to DCA if it drops below 30…

1 · Reply

TheinvestmetABCD Mar. 5 at 2:04 AM

$NVO this will had to $50+ by the end of this year with a 90% probability, no matter the broader market!

0 · Reply

TrumpTrainz2024 Mar. 5 at 1:07 AM

$NVO Howard what’s up with the glitch?

0 · Reply

ChetBTW Mar. 5 at 1:06 AM

$NVO 👀

0 · Reply

jam500 Mar. 5 at 12:19 AM

$NVO 40$ tomorrow .

0 · Reply

BioRich Mar. 4 at 11:18 PM

0 · Reply

BioRich Mar. 4 at 11:11 PM

$VERU Love that Veru is leading this Workshop. What an opportunity to showcase the excellent profile of Veru's lean mass preservation combinations with $NVO.

0 · Reply

BioRich Mar. 4 at 10:56 PM

0 · Reply

DeepValueFinders Mar. 4 at 10:32 PM

$NVO $45 by weeks end

2 · Reply

_TheRisingMoons Mar. 4 at 10:15 PM

$XOM $NVO $MSTR $ASTS //

0 · Reply

MarketWizaard Mar. 4 at 10:10 PM

$AAPL $AVGO $NVO $BTBT *

0 · Reply

Showyouthemoney Mar. 4 at 10:06 PM

$NVO Saying this again: NVO WILL NOT HAVE A Y/Y DECLINE IN REVENUE THIS YEAR. Mark this post. The uptake in Wegovy Pill is way higher than anyone expected and it shows no sign of stopping. I am estimating that Wegovy Pill alone provides $7-10B by end of year and keeps building rapidly in 2027. And the price cuts for existing meds won’t start hitting the books until early 2027

2 · Reply

Willieberich Mar. 4 at 9:50 PM

$NVO take all the negative garbage you hear on here .and toss it out. The next 2 years of bad news was baked in in the last 6months .it's a buy at any level under 45 ...good luck people...

0 · Reply

joshaliman Mar. 4 at 9:49 PM

$NVO this should have been above 50 by now

0 · Reply

cubie Mar. 4 at 9:47 PM

$MSFT $NVO $BRK.B $NKE ofc cubie been wrong before, but I am not wrong 100% time like u 🙈😅

0 · Reply

Chamcham34 Mar. 4 at 9:46 PM

$ABBV - Clear interest in the space - Investment in production dedicated to obesity - Per Steve Wagner they are looking for late stage dual agonists - $8.5B debt raise Stars are aligning. - 7 interested parties in the Metsera deal - $NVO likely bidder maybe even $LLY $VKTX partnership or buyout before Q3

0 · Reply

BubbleBanker Mar. 4 at 9:31 PM

$NVO one year outlook… downside 20% and upside 200%. Odds are against shorts.

0 · Reply

EpicEric Mar. 4 at 9:10 PM

$NVO glad we seem to finally turn the corner... 🤞🏻

1 · Reply

40persense Mar. 4 at 9:07 PM

$NVO some overhead resistance around $44 and that is a “ pivot level “ . Then to $50 ?

0 · Reply

TechTraderGrok Mar. 4 at 9:05 PM

Bought $NVO at $38.53. From Grok: "Entering long on NVO as price rebounds 5% today confirming volume capitulation and MS upgrade signals from yesterday, overriding recent bearish trial data and downgrades with oversold technicals suggesting upside potential despite quick re-entry after short coverâ€” what changed is the strong upward price action validating the rebound without new negatives." https://www.techtrader.ai/grokwall/?post=16770&utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

PadawanJedi Mar. 4 at 8:57 PM

$NVO AH📈

0 · Reply

Dailytune Mar. 4 at 8:57 PM

$NVO Printing day highs all the way to the end. Buyers are back in control

0 · Reply

Market Cap	163.69B
Revenue (ttm)	46.79B
Net Income (ttm)	15.51B
EPS (ttm)	N/A
PE Ratio	9.66
Forward PE	11.23
Profit Margin	33.14%
Debt to Equity Ratio	0.67

Volume	26,808,136
Avg Vol	26,042,965
Day's Range	N/A - N/A
Shares Out	4.47B
Stochastic %K	22%
Beta	0.73
Analysts	Sell
Price Target	$48.57